Daehan New Pharm Co. Ltd (KQ:054670) — Market Cap & Net Worth
Market Cap & Net Worth: Daehan New Pharm Co. Ltd (054670)
Daehan New Pharm Co. Ltd (KQ:054670) has a market capitalization of $67.63 Million (₩99.79 Billion) as of May 5, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #20708 globally and #1251 in its home market, demonstrating a -0.84% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Daehan New Pharm Co. Ltd's stock price ₩7110.00 by its total outstanding shares 14035289 (14.04 Million). Analyse 054670 operating cash flow to see how efficiently the company converts income to cash.
Daehan New Pharm Co. Ltd Market Cap History: 2015 to 2026
Daehan New Pharm Co. Ltd's market capitalization history from 2015 to 2026. Data shows change from $142.30 Million to $67.63 Million (-8.81% CAGR).
Index Memberships
Daehan New Pharm Co. Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$299.07 Billion | 0.02% | #581 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$299.07 Billion | 0.02% | #581 of 1384 |
Weight: Daehan New Pharm Co. Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Daehan New Pharm Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Daehan New Pharm Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Daehan New Pharm Co. Ltd's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.00x
Daehan New Pharm Co. Ltd's market cap is 0.00 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $142.30 Million | $90.23 Billion | $4.15 Billion | 0.00x | 0.03x |
| 2016 | $178.69 Million | $109.40 Billion | -$5.67 Billion | 0.00x | N/A |
| 2017 | $125.59 Million | $130.82 Billion | -$20.58 Billion | 0.00x | N/A |
| 2018 | $93.27 Million | $119.53 Billion | $2.45 Billion | 0.00x | 0.04x |
| 2019 | $96.04 Million | $134.10 Billion | $15.24 Billion | 0.00x | 0.01x |
| 2020 | $116.35 Million | $149.51 Billion | -$9.93 Billion | 0.00x | N/A |
| 2021 | $101.38 Million | $166.59 Billion | $15.69 Billion | 0.00x | 0.01x |
| 2022 | $80.33 Million | $197.96 Billion | $24.32 Billion | 0.00x | 0.00x |
| 2023 | $86.08 Million | $204.22 Billion | $12.54 Billion | 0.00x | 0.01x |
| 2024 | $65.34 Million | $202.19 Billion | $15.47 Billion | 0.00x | 0.00x |
Competitor Companies of 054670 by Market Capitalization
Companies near Daehan New Pharm Co. Ltd in the global market cap rankings as of May 5, 2026.
Key companies related to Daehan New Pharm Co. Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.15 |
Daehan New Pharm Co. Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Daehan New Pharm Co. Ltd's market cap moved from $142.30 Million to $ 67.63 Million, with a yearly change of -8.81%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩67.63 Million | +8.22% |
| 2025 | ₩62.49 Million | -4.37% |
| 2024 | ₩65.34 Million | -24.09% |
| 2023 | ₩86.08 Million | +7.16% |
| 2022 | ₩80.33 Million | -20.77% |
| 2021 | ₩101.38 Million | -12.87% |
| 2020 | ₩116.35 Million | +21.15% |
| 2019 | ₩96.04 Million | +2.97% |
| 2018 | ₩93.27 Million | -25.74% |
| 2017 | ₩125.59 Million | -29.72% |
| 2016 | ₩178.69 Million | +25.57% |
| 2015 | ₩142.30 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Daehan New Pharm Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $67.63 Million USD |
| MoneyControl | $67.63 Million USD |
| MarketWatch | $67.63 Million USD |
| marketcap.company | $67.63 Million USD |
| Reuters | $67.63 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Daehan New Pharm Co. Ltd
Daehan Nupharm Co.,Ltd. manufactures and sells pharmaceuticals and veterinary products in South Korea and internationally. It offers pharmaceuticals drugs for cardiovascular, endocrine system, neuropsychiatric, gastrointestinal, respiratory system, antipyretic, analgesic, anti-inflammatory, anti-infective, musculoskeletal, osteoporosis, anti-cancer, urogenital system, antifungal, antiviral, hormo… Read more